吉西他滨
生物
胰腺癌
PI3K/AKT/mTOR通路
蛋白激酶B
癌症研究
癌变
腺癌
内科学
信号转导
化疗
肿瘤科
癌症
医学
细胞生物学
遗传学
作者
Fangyu Zhao,Gang Ye,Jiangdong Qiu,Yueze Liu,Jinxin Tao,Guangyu Chen,Dan Su,Lei You,Lianfang Zheng,Taiping Zhang,Yupei Zhao
摘要
Pancreatic ductal adenocarcinoma (PDAC) has a poor response to the first-line chemotherapy drug gemcitabine. We previously identified stanniocalcin-1 as a gemcitabine-resistant-related gene, but its specific role and function in pancreatic cancer remain unclear. RT-qPCR and Western blot were used to evaluate differential protein and mRNA expressions. The biological functions of genes were determined using proliferation and drug-resistance experiments. Subcutaneous tumorigenesis experiment was performed on nude mice. Prognostic analysis was performed using public databases and our clinical data. We found HIF-1α-regulated STC1 expression mediated chemoresistance in pancreatic cancer. Deeper, we explored the action mechanism of STC1 and identified PI3K/AKT as the downstream signaling pathway of STC1. Furthermore, we analyzed clinical data and found that STC1 expression was related to the prognosis of gemcitabine-treated patients after surgery. In general, we proved the HIF-1α/STC1/PI3K-AKT axis participated in PDAC progression and chemoresistance, and STC1 may serve as a potential prognostic factor and therapeutic target for PDAC treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI